The Role of LPPV: Ensuring Stronger Pharmacovigilance Oversight

In an increasingly complex regulatory landscape, the role of the Local Person for Pharmacovigilance (LPPV) has become critically important. While Qualified Persons for Pharmacovigilance (QPPVs) and global safety teams often take center stage in pharmacovigilance strategy, the importance of LPPVs at the national level might be underestimated. The written expectations of National Competent Authority (NCA) from local PV person may vary country by country. However systemic view proposes to have unified approach on having LPPV as a country level PV representative of MAH, who is expected to ensure the local implementation of the pharmacovigilance system in alignment with national requirements. To enable LPPVs to act in this role full picture information is needed for every LPPV.

Not Merely a Formality: The LPPV as Compliance Representative

The list of LPPVs is included in PSMF Annex A, which is dedicated to the QPPV function. If the role and responsibilities of LPPVs are interpreted differently across countries, or if the importance of the role is underestimated globally, there is a risk that LPPVs may not be able to fulfil their regulatory obligations effectively due to limited access to the information required for robust oversight of the local pharmacovigilance system.

In addition, LPPVs must be able to respond to regulatory authority inquiries, manage country-specific pharmacovigilance obligations (such as literature screening and/or expedited reporting), and demonstrate appropriate local oversight during inspections. Insufficient recognition of the role or restricted access to relevant information may compromise their ability to perform these responsibilities in accordance with regulatory requirements

Instances where LPPVs are uninformed about centrally managed signal activities, risk minimisation measures, or submission timelines may result in critical findings during inspections. These findings may reflect deficiencies in the MAH’s overall pharmacovigilance governance.

Expectations During National Inspections

Even MAHs with products authorized exclusively through the centralized procedure are subject to national pharmacovigilance (PV) inspections. As these inspections are often conducted in the national language, representation by the Local Person Responsible for Pharmacovigilance (LPPV) is essential to ensure effective communication with inspectors.

The LPPV should be able to explain how global PV processes are implemented at the national level and demonstrate a sound understanding of the company’s global PV system. In addition, the LPPV is expected to demonstrate knowledge of all local PV activities and related documentation, including local training records, literature screening, case handling, and applicable SOPs.

The LPPV should also be able to demonstrate awareness of country-specific regulatory requirements and timelines, and present relevant documentation such as deviation reports, internal audit findings, and records of interactions with the national competent authority.

Failure to demonstrate these capabilities may be regarded as non-compliance and could result in regulatory findings and reputational risks for the MAH.

Recommended Integration Measures

The measures required to ensure inspection readiness while maintaining a well-functioning pharmacovigilance (PV) system are not overly complex. Marketing Authorisation Holders (MAHs) must establish an effective process for integrating Local Persons Responsible for Pharmacovigilance (LPPVs) into the global PV system.

In some countries, regulations specifically require LPPVs to have direct access to the MAH’s safety database and PV documentation. In other jurisdictions, such requirements are not explicitly stated in legislation. Nevertheless, it is generally expected that LPPVs maintain oversight of the MAH’s overall PV system. This can be achieved by providing access to, or copies of, key PV documents and information, including the Pharmacovigilance System Master File (PSMF), signal management activities, Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), additional Risk Minimisation Measures (aRMMs), ongoing and planned studies, the outcomes of safety-related programmes, safety database validation status and version history, and any changes to a product’s safety profile.

As a good practice, information should be shared according to its potential impact on the local PV system. For example, changes to a product’s safety profile should be communicated without delay, whereas information on PSUR submissions or safety database upgrades may be discussed during routine QPPV–LPPV meetings.

LPPVs must receive appropriate initial training, and their continuous development should be maintained, particularly regarding local regulatory requirements. Training records should be documented and retained in an audit-ready format.

Furthermore, inspection preparedness should be strengthened through mock audits, inspection simulations, and role-based scenario planning involving the LPPV. These activities help ensure consistent responses during inspections and facilitate timely retrieval of required documentation. Finally, clear and transparent communication channels between global safety functions, regional hubs, and LPPVs are essential to support proactive compliance and alignment with local regulatory expectations

Pharmacovigilance Integrity Through Local Oversight

The LPPV function contributes to the overall pharmacovigilance system by incorporating local knowledge, linguistic fluency, and regulatory proximity. Timely identification of adverse events, literature monitoring in local languages, adaptation of risk minimisation measures, and liaison with national authorities all fall within the LPPV’s scope. Enabling this function supports early identification of potential issues and fosters a safety culture that is responsive at both global and local levels. LPPVs serve as operational bridges, translating global strategies into local execution.

Strategic Relevance Beyond Compliance

A well-supported LPPV framework not only addresses legal requirements but also demonstrates organisational commitment to patient safety. In-country expertise, when leveraged effectively, strengthens pharmacovigilance outcomes and promotes confidence among stakeholders, including regulators. The LPPV should be recognised as a strategic contributor to the pharmacovigilance system — capable of influencing safety outcomes, reducing inspection findings, and enhancing the MAH’s regulatory posture.

The LPPV role is a vital component of the EU pharmacovigilance framework. Comprehensive integration, consistent training, access to relevant systems, and structured collaboration with central functions are essential to fulfilling both regulatory expectations and internal quality standards. Establishing a robust local pharmacovigilance presence enhances inspection readiness, supports risk management, and reinforces trust in the MAH’s safety commitment. For organisations reviewing their LPPV setup or aiming to strengthen local oversight, the adoption of clear procedures, defined responsibilities, and measurable oversight indicators can serve as a foundation for sustainable compliance.